PHARMACY

FDA approves new indication for Regeneron, Sanofi’s Dupixent

Dupixent is now approved as an add-on maintenance treatment for patients ages 6 to 11 years old with moderate to severe asthma.
NCPA, MPECrx launch Pathways to Pharmacy Ownership initiative

Pathways to Pharmacy Ownership is an initiative from the National Community Pharmacists Association and Minority Pharmacist Entrepreneur Conference that encourages and supports independent pharmacy ownership among minority pharmacists.

FDA authorizes Moderna, J&J COVID-19 booster shots, clears mix-and-match brands

The FDA plans to further assess the benefits and risks of the use of booster doses in additional populations, and update the healthcare community and public in the coming weeks.
Walgreens Boots Alliance highlights expanding mental health resources

Walgreens Boots Alliance is expanding mental health first aid training for more than 27,000 Walgreens pharmacists, and rolling out new services to meet the growing need in communities across Europe and the United Kingdom.
White House details COVID-19 vaccine plan for children ages 5 to 11 years old

The Biden Administration said it has secured enough supply to vaccinate 28 million children between the ages of 5 to 11 years old who would become eligible for COVID-19 vaccination if authorization is given.
Adamis secures FDA nod for Zimhi

Zimhi is a high-dose naloxone product for the treatment of opioid overdose.
FDA OKs new indication for Roche’s Tecentriq

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting, the company said.
Alembic intros doxycycline hyclate

Alembic's doxycycline hyclate is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
FSD Pharma inks deal with Covar for development of Lucid-PSYCH

FSD Pharma has entered into an agreement with Covar Pharmaceuticals to commence work on providing research quantities of FSD’s drug candidate, Lucid-PSYCH.
Dr. Reddy’s obtains FDA nod for generic Revlimid

Dr. Reddy’s is eligible for 180 days of generic drug exclusivity for lenalidomide capsules in 2.5 mg and 20 mg dosage strengths.
AAM presents facts, figures during Breast Cancer Awareness Month

Generic and biosimilar prescription medicines represent significant savings for U.S. breast cancer patients and the overall health system.
FDA expected to approve mix-and-match COVID-19 boosters

The Food and Drug Administration is expected to authorize boosters of the Moderna and Johnson & Johnson COVID-19 vaccines by Oct. 20, at which time it could also allow the mix and match of boosters.
Walgreens once again tracking flu activity

Walgreens Flu Index shows that flu activity is up 23% compared to last flu season as people return to more in-person activities.
Dr. Reddy's unveils generic BiCNU

The BiCNU brand and generic had a market value of approximately $19.4 million for the most recent 12 months ended August 2021, according to IQVIA.

News and information on retail pharmacy, including generic drugs, branded drugs, specialty pharmacy medications, pharmacy technology and legislative updates.